These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7896213)

  • 1. Interferon-alpha 2a therapy in CML: disappearance of BCR/ABL transcript in a case of long-lasting continuous cytogenetic conversion.
    Pardini S; Addis M; Dore F; Bonfigli S; Nieddu RM; Galanello R; Longinotti M; Pau MG
    Haematologica; 1994; 79(6):540-1. PubMed ID: 7896213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
    J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
    Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
    Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
    Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
    J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
    Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
    Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T; Tamura S; Takemoto Y; Kakishita E
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
    Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
    Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 2000 Jan; 95(1):62-6. PubMed ID: 10607685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
    Manley R; Cochrane J; McDonald M; Rigby S; Moore A; Kirk A; Clarke S; Crossen PE; Morris CM; Patton WN
    Leukemia; 1999 Jan; 13(1):126-9. PubMed ID: 10049047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.